Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Convertible Debt (2016 - 2022)

Historic Convertible Debt for Ligand Pharmaceuticals (LGND) over the last 8 years, with Q1 2022 value amounting to $176.5 million.

  • Ligand Pharmaceuticals' Convertible Debt fell 4989.11% to $176.5 million in Q1 2022 from the same period last year, while for Mar 2022 it was $176.5 million, marking a year-over-year decrease of 4989.11%. This contributed to the annual value of $320.7 million for FY2021, which is 2748.77% down from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Convertible Debt stood at $176.5 million for Q1 2022, which was down 4989.11% from $320.7 million recorded in Q4 2021.
  • In the past 5 years, Ligand Pharmaceuticals' Convertible Debt registered a high of $639.0 million during Q4 2019, and its lowest value of $176.5 million during Q1 2022.
  • Over the past 5 years, Ligand Pharmaceuticals' median Convertible Debt value was $452.3 million (recorded in 2020), while the average stood at $474.6 million.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Convertible Debt skyrocketed by 477.07% in 2019, and later plummeted by 4989.11% in 2022.
  • Over the past 5 years, Ligand Pharmaceuticals' Convertible Debt (Quarter) stood at $609.9 million in 2018, then increased by 4.77% to $639.0 million in 2019, then plummeted by 30.78% to $442.3 million in 2020, then dropped by 27.49% to $320.7 million in 2021, then plummeted by 44.95% to $176.5 million in 2022.
  • Its last three reported values are $176.5 million in Q1 2022, $320.7 million for Q4 2021, and $316.9 million during Q3 2021.